Parkinson's Disease Market Size, Share, Trends, Growth Outlook

Parkinson's Disease Market is estimated to increase at a growth rate of 7.4% CAGR over the forecast period from 2024 to 2030.

The global Parkinson's Disease Market Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Drug Class (Levodopa/Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-Inhibitors, Anticholinergics, Others), By Device (Deep Brain Stimulation (DBS) Devices, Carbidopa/Levodopa Enteral Suspension (Duopa) Delivery Devices), By Route of Administration (Oral, Transdermal, Subcutaneous, Intestinal Infusion, Others), By Distribution Channel (Hospitals, Clinics, Retail Pharmacies, Online, Others).

An Introduction to Parkinson's Disease Market in 2024

The Parkinson's Disease Market in 2024 addresses the multifaceted challenges associated with managing Parkinson's disease (PD), a progressive neurodegenerative disorder characterized by motor impairments, cognitive decline, and nonmotor symptoms. As the prevalence of PD rises with aging populations worldwide, the market for Parkinson's disease therapeutics and management solutions continues to expand, driven by a growing understanding of disease pathophysiology and evolving treatment paradigms. Therapeutic interventions for Parkinson's disease encompass a spectrum of pharmacological agents, neurostimulation therapies, and rehabilitative approaches aimed at alleviating motor symptoms, enhancing quality of life, and slowing disease progression. Moreover, with emerging insights into the role of neuroinflammation, mitochondrial dysfunction, and protein aggregation in PD pathogenesis, stakeholders focus on developing disease-modifying therapies and personalized treatment strategies, thereby fostering innovation and improving outcomes for individuals living with Parkinson's disease.

Parkinson's Disease Market Competitive Landscape

The global Parkinson's Disease Industry is highly competitive with a large number of companies focusing on niche market segments. Amidst intense competitive conditions, Parkinson's Disease Companies are investing in new product launches and strengthening distribution channels. Key companies operating in the Parkinson's Disease Industry include- AbbVie Inc, ACADIA Pharmaceuticals Inc, Apotex Inc, Bausch Health, Boehringer Ingelheim International GmbH, Cipla Inc, Daiichi Sankyo Company Ltd, Dr. Reddy’s Laboratories Ltd, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Impax Laboratories LLC, Lundbeck, Merck & Co. Inc, Mylan N.V, Novartis AG, Orion Corp, Par Pharmaceutical, STADA Arzneimittel AG, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, UCB SA, WOCKHARDT.

Market Trend: Advancements in Disease Understanding and Treatment

A prominent trend in the Parkinson's Disease Market is the continuous advancements in understanding the disease's pathophysiology and the development of innovative treatment approaches. With ongoing research, there is a deeper understanding of the underlying mechanisms of Parkinson's disease, leading to the discovery of potential therapeutic targets and novel treatment modalities such as gene therapy, stem cell therapy, and disease-modifying drugs.

Market Driver: Aging Population and Increasing Disease Prevalence

The primary driver for the Parkinson's Disease Market is the aging population globally and the consequent rise in the prevalence of Parkinson's disease. As the elderly population grows, the incidence and prevalence of age-related neurodegenerative disorders like Parkinson's disease also increase. This demographic shift drives the demand for effective treatments, driving investments in research, drug development, and healthcare infrastructure to manage Parkinson's disease.

Parkinson's Disease Market Opportunity:Personalized Medicine and Precision Therapeutics

An opportunity in the Parkinson's Disease Market lies in the advancement of personalized medicine and precision therapeutics. Tailoring treatment approaches based on individual patient characteristics, genetic profiles, and disease progression can enhance treatment efficacy, minimize side effects, and improve patient outcomes. Embracing precision medicine approaches, including biomarker-based diagnostics and targeted therapies, can revolutionize Parkinson's disease management, offering more personalized and effective treatment options for patients.

Parkinson's Disease Market Share Analysis: Deep Brain Stimulation (DBS) Devices is the fastest growing market segment over the forecast period to 2030

Deep Brain Stimulation (DBS) devices emerge as the segment experiencing the fastest growth within Parkinson's Disease management. This surge is driven by several significant factors. Firstly, DBS has gained traction as an effective treatment option for Parkinson's Disease, particularly for patients experiencing motor fluctuations and medication refractory symptoms. DBS involves the surgical implantation of electrodes into specific areas of the brain, which deliver electrical impulses to modulate abnormal neural activity associated with Parkinson's Disease, providing symptomatic relief and improving motor function. Secondly, advancements in DBS technology, including improvements in electrode design, surgical techniques, and programming algorithms, have enhanced treatment outcomes and expanded the eligibility criteria for DBS therapy. Additionally, the growing acceptance and utilization of DBS by neurologists and neurosurgeons, along with increasing patient awareness and demand for minimally invasive treatment options, contribute to the rapid growth of DBS devices. Moreover, the availability of DBS devices through various distribution channels, including hospitals and specialized clinics, enhances accessibility to this advanced therapy for Parkinson's Disease patients worldwide. As the understanding of Parkinson's Disease pathophysiology evolves and the demand for effective long-term management options increases, DBS devices are poised to play a pivotal role in improving quality of life and functional outcomes for patients with Parkinson's Disease.

Parkinson's Disease Market Segmentation

By Drug Class
Levodopa/Carbidopa
Dopamine Receptor Agonists
MAO-Inhibitors
COMT-Inhibitors
Anticholinergics
Others
By Device
Deep Brain Stimulation (DBS) Devices
Carbidopa/Levodopa Enteral Suspension (Duopa) Delivery Devices
By Route of Administration
Oral
Transdermal
Subcutaneous
Intestinal Infusion
Others
By Distribution Channel
Hospitals
Clinics
Retail Pharmacies
Online
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Parkinson's Disease Companies

AbbVie Inc
ACADIA Pharmaceuticals Inc
Apotex Inc
Bausch Health
Boehringer Ingelheim International GmbH
Cipla Inc
Daiichi Sankyo Company Ltd
Dr. Reddy’s Laboratories Ltd
F. Hoffmann-La Roche Ltd
GlaxoSmithKline plc
Impax Laboratories LLC
Lundbeck
Merck & Co. Inc
Mylan N.V
Novartis AG
Orion Corp
Par Pharmaceutical
STADA Arzneimittel AG
Sun Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd
UCB SA
WOCKHARDT
* List not Exhaustive

Reasons to Buy the Parkinson's Disease Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Parkinson's Disease Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Parkinson's Disease Industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Parkinson's Disease Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Parkinson's Disease Market Size Outlook, $ Million, 2021 to 2030
3.2 Parkinson's Disease Market Outlook by Type, $ Million, 2021 to 2030
3.3 Parkinson's Disease Market Outlook by Product, $ Million, 2021 to 2030
3.4 Parkinson's Disease Market Outlook by Application, $ Million, 2021 to 2030
3.5 Parkinson's Disease Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Parkinson's Disease Industry
4.2 Key Market Trends in Parkinson's Disease Industry
4.3 Potential Opportunities in Parkinson's Disease Industry
4.4 Key Challenges in Parkinson's Disease Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Parkinson's Disease Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Parkinson's Disease Market Outlook by Segments
7.1 Parkinson's Disease Market Outlook by Segments, $ Million, 2021- 2030
By Drug Class
Levodopa/Carbidopa
Dopamine Receptor Agonists
MAO-Inhibitors
COMT-Inhibitors
Anticholinergics
Others
By Device
Deep Brain Stimulation (DBS) Devices
Carbidopa/Levodopa Enteral Suspension (Duopa) Delivery Devices
By Route of Administration
Oral
Transdermal
Subcutaneous
Intestinal Infusion
Others
By Distribution Channel
Hospitals
Clinics
Retail Pharmacies
Online
Others
8 North America Parkinson's Disease Market Analysis and Outlook To 2030
8.1 Introduction to North America Parkinson's Disease Markets in 2024
8.2 North America Parkinson's Disease Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Parkinson's Disease Market size Outlook by Segments, 2021-2030
By Drug Class
Levodopa/Carbidopa
Dopamine Receptor Agonists
MAO-Inhibitors
COMT-Inhibitors
Anticholinergics
Others
By Device
Deep Brain Stimulation (DBS) Devices
Carbidopa/Levodopa Enteral Suspension (Duopa) Delivery Devices
By Route of Administration
Oral
Transdermal
Subcutaneous
Intestinal Infusion
Others
By Distribution Channel
Hospitals
Clinics
Retail Pharmacies
Online
Others
9 Europe Parkinson's Disease Market Analysis and Outlook To 2030
9.1 Introduction to Europe Parkinson's Disease Markets in 2024
9.2 Europe Parkinson's Disease Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Parkinson's Disease Market Size Outlook by Segments, 2021-2030
By Drug Class
Levodopa/Carbidopa
Dopamine Receptor Agonists
MAO-Inhibitors
COMT-Inhibitors
Anticholinergics
Others
By Device
Deep Brain Stimulation (DBS) Devices
Carbidopa/Levodopa Enteral Suspension (Duopa) Delivery Devices
By Route of Administration
Oral
Transdermal
Subcutaneous
Intestinal Infusion
Others
By Distribution Channel
Hospitals
Clinics
Retail Pharmacies
Online
Others
10 Asia Pacific Parkinson's Disease Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Parkinson's Disease Markets in 2024
10.2 Asia Pacific Parkinson's Disease Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Parkinson's Disease Market size Outlook by Segments, 2021-2030
By Drug Class
Levodopa/Carbidopa
Dopamine Receptor Agonists
MAO-Inhibitors
COMT-Inhibitors
Anticholinergics
Others
By Device
Deep Brain Stimulation (DBS) Devices
Carbidopa/Levodopa Enteral Suspension (Duopa) Delivery Devices
By Route of Administration
Oral
Transdermal
Subcutaneous
Intestinal Infusion
Others
By Distribution Channel
Hospitals
Clinics
Retail Pharmacies
Online
Others
11 South America Parkinson's Disease Market Analysis and Outlook To 2030
11.1 Introduction to South America Parkinson's Disease Markets in 2024
11.2 South America Parkinson's Disease Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Parkinson's Disease Market size Outlook by Segments, 2021-2030
By Drug Class
Levodopa/Carbidopa
Dopamine Receptor Agonists
MAO-Inhibitors
COMT-Inhibitors
Anticholinergics
Others
By Device
Deep Brain Stimulation (DBS) Devices
Carbidopa/Levodopa Enteral Suspension (Duopa) Delivery Devices
By Route of Administration
Oral
Transdermal
Subcutaneous
Intestinal Infusion
Others
By Distribution Channel
Hospitals
Clinics
Retail Pharmacies
Online
Others
12 Middle East and Africa Parkinson's Disease Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Parkinson's Disease Markets in 2024
12.2 Middle East and Africa Parkinson's Disease Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Parkinson's Disease Market size Outlook by Segments, 2021-2030
By Drug Class
Levodopa/Carbidopa
Dopamine Receptor Agonists
MAO-Inhibitors
COMT-Inhibitors
Anticholinergics
Others
By Device
Deep Brain Stimulation (DBS) Devices
Carbidopa/Levodopa Enteral Suspension (Duopa) Delivery Devices
By Route of Administration
Oral
Transdermal
Subcutaneous
Intestinal Infusion
Others
By Distribution Channel
Hospitals
Clinics
Retail Pharmacies
Online
Others
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
AbbVie Inc
ACADIA Pharmaceuticals Inc
Apotex Inc
Bausch Health
Boehringer Ingelheim International GmbH
Cipla Inc
Daiichi Sankyo Company Ltd
Dr. Reddy’s Laboratories Ltd
F. Hoffmann-La Roche Ltd
GlaxoSmithKline plc
Impax Laboratories LLC
Lundbeck
Merck & Co. Inc
Mylan N.V
Novartis AG
Orion Corp
Par Pharmaceutical
STADA Arzneimittel AG
Sun Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd
UCB SA
WOCKHARDT
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Drug Class
Levodopa/Carbidopa
Dopamine Receptor Agonists
MAO-Inhibitors
COMT-Inhibitors
Anticholinergics
Others
By Device
Deep Brain Stimulation (DBS) Devices
Carbidopa/Levodopa Enteral Suspension (Duopa) Delivery Devices
By Route of Administration
Oral
Transdermal
Subcutaneous
Intestinal Infusion
Others
By Distribution Channel
Hospitals
Clinics
Retail Pharmacies
Online
Others